FDA Investigates Sevoflurane Safety After Neurologic Deaths Linked to Mitochondrial Variant in Venezuelan-Ancestry Patients

An active FDA safety investigation into sevoflurane and volatile anesthetics is now on record, and manufacturers of inhaled anesthetic agents face a credible near-term risk of labeling revisions and updated risk communication requirements. The agency is reviewing published scientific reports of catastrophic neurologic outcomes, including death, in adult and pediatric patients of maternal Venezuelan ancestry following routine general anesthesia.

At the center of the investigation is a rare mitochondrial genetic variant, MT-ND4 m.11232T>C, identified in a subset of patients who experienced serious adverse events after sevoflurane exposure. Although reported cases are currently linked to sevoflurane specifically, FDA has flagged concern across the entire class of volatile anesthetics, widening the regulatory perimeter beyond a single product or manufacturer.

The agency has issued interim clinical guidance for healthcare providers and relief organizations operating in Venezuela, a population of heightened relevance given recent seismic events in the country. Where clinically appropriate and available, FDA recommends considering alternatives to volatile anesthetics, including intravenous anesthetics or regional anesthesia, for patients of maternal Venezuelan ancestry until the review concludes.

For QA directors and regulatory affairs leads at anesthetic manufacturers, the pharmacovigilance read is immediate. FDA's investigation is ongoing, and the agency is actively soliciting adverse event data through its MedWatch program. Manufacturers should assess whether existing signal detection workflows and expedited reporting timelines under 21 CFR Part 314 are calibrated to capture genotype-linked adverse events, a category that may not be well-represented in legacy case intake forms. CAPA documentation should reflect any gaps identified in current pharmacovigilance SOPs.

The class-wide concern also has implications for post-market surveillance obligations under ICH E2E pharmacovigilance planning principles. If FDA's review determines that labeling changes are warranted, manufacturers will need to move quickly through the labeling revision and distribution notification process, particularly for products already in field inventory or humanitarian supply chains.

Adverse events can be submitted to FDA's MedWatch program online or by calling 1-800-332-1088; fax submission is available at 1-800-FDA-0178.

The pace of FDA's review and the breadth of any resulting labeling action will depend substantially on the volume and quality of MedWatch reports received during the current investigation window.

Source: FDA Drugs Safety Alerts and Statements via FDA.gov, 2 July 2026.